Akebia Therapeutics is a pharmaceutical company, which focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The Company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme.

Employee Rating

3.4More
TypePublic
HQCambridge, US
Founded2007
Size (employees)90 (est)
Websiteakebia.com
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Akebia Therapeutics Office Locations

Akebia Therapeutics has an office in Cambridge
Cambridge, (HQ)
1100 245 First St
Show all (1)
Report incorrect company information

Akebia Therapeutics Financials and Metrics

Akebia Therapeutics Revenue

USD

Net income (Q3, 2018)

(26.0m)

EBIT (Q3, 2018)

(27.8m)

Market capitalization (4-Dec-2018)

474.7m

Closing stock price (4-Dec-2018)

8.3

Cash (30-Sep-2018)

162.4m
Akebia Therapeutics's current market capitalization is $474.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

12.5m18.5m22.2m27.0m

R&D expense

25.4m43.0m115.8m230.9m

Operating expense total

37.9m61.5m138.0m257.9m

EBIT

(37.9m)(61.5m)(136.5m)(79.9m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

3.8m2.3m2.9m3.4m3.7m3.9m5.8m5.3m4.9m5.8m6.9m6.7m9.0m12.5m10.4m

R&D expense

6.2m5.5m6.6m7.5m7.2m15.8m20.2m30.9m31.2m60.0m43.8m58.7m61.4m71.9m70.6m

Operating expense total

9.9m7.8m9.6m10.9m10.9m19.7m26.0m36.2m36.2m65.8m50.7m65.5m70.4m84.5m81.0m

EBIT

(9.9m)(7.8m)(9.6m)(10.9m)(10.9m)(19.7m)(26.0m)(36.2m)(36.2m)(45.0m)(22.1m)(24.2m)(24.5m)(35.7m)(27.8m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8m49.8m187.3m70.2m

Accounts Receivable

48.0k933.0k34.2m

Inventories

1.5m2.6m2.2m

Current Assets

110.5m141.0m296.3m358.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

126.3m95.4m49.7m27.9m76.2m66.7m43.4m46.2m65.8m87.3m125.4m89.6m158.2m163.5m162.4m

Accounts Receivable

119.4k114.0k57.0k74.0k48.0k14.0k35.9m132.0k688.0k

Current Assets

133.7m126.1m119.8m102.7m155.0m158.8m219.5m192.5m165.1m255.1m332.4m333.9m437.0m407.4m397.5m

PP&E

181.0k204.9k404.0k398.0k479.0k629.0k1.8m2.7m2.9m2.9m3.4m3.7m3.7m3.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(37.0m)(60.7m)(135.7m)(76.9m)

Depreciation and Amortization

49.4k96.0k296.0k617.0k

Inventories

(773.0k)(1.0m)428.0k

Accounts Payable

4.1m231.0k(274.0k)5.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.7m)(10.7m)(21.4m)(40.9m)(25.8m)(61.6m)(36.3m)(44.5m)(66.1m)(89.2m)(23.4m)(57.5m)(83.5m)

Depreciation and Amortization

8.1k50.0k85.0k78.0k253.0k420.0k199.0k413.0k638.0k

Accounts Payable

1.9m1.5m3.0m4.3m(987.0k)7.3m2.4m2.8m8.5m15.1m8.2m6.7m10.9m(2.2m)5.7m

Cash From Operating Activities

(6.0m)(20.5m)(29.5m)(9.5m)14.8m(39.8m)(20.3m)(11.3m)(23.8m)
USDY, 2018

Financial Leverage

2.8 x
Show all financial metrics
Report incorrect company information

Akebia Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Akebia Therapeutics News and Updates

Report incorrect company information

Akebia Therapeutics Blogs

Akebia Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that it will participate in

Reni Benjamin

Reni Benjamin jennifer.segal… Tue, 08/14/2018 - 11:39 Reni Benjamin Raymond James ren.benjamin@raymondjames.com

Akebia Therapeutics Announces Second Quarter 2018 Financial Results

Akebia Therapeutics Announces Second Quarter 2018 Financial Results Content Import Wed, 08/08/2018 - 16:08 Akebia Therapeutics Announces Second Quarter 2018 Financial Results August 8, 2018 at 4:05 PM EDT This release is a backfill from a News Wire …

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Content Import Thu, 08/02/2018 - 16:07 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 2, 2018 at 4:05 PM EDT This release is a backfil…

Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast

Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast Content Import Wed, 08/01/2018 - 16:07 Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast August 1, 2018 at 4:05 PM EDT This release is a backfill fr…

Akebia Therapeutics Company Life and Culture

Report incorrect company information

Akebia Therapeutics Frequently Asked Questions

  • When was Akebia Therapeutics founded?

    Akebia Therapeutics was founded in 2007.

  • How many employees does Akebia Therapeutics have?

    Akebia Therapeutics has 90 employees.

  • Who are Akebia Therapeutics competitors?

    Competitors of Akebia Therapeutics include Atopix, Biothera and Hospira.

  • Where is Akebia Therapeutics headquarters?

    Akebia Therapeutics headquarters is located at 1100 245 First St, Cambridge.

  • Where are Akebia Therapeutics offices?

    Akebia Therapeutics has an office in Cambridge.

  • How many offices does Akebia Therapeutics have?

    Akebia Therapeutics has 1 office.